Literature DB >> 8181244

Co-ordination of diabetes care in the primary and the secondary health care system in Denmark. Danish National Board of Health.

N D Olivarius1, T Lauritzen, H Beck-Nielsen, J Fog, C E Mogensen.   

Abstract

In Denmark the co-operation between the primary and secondary health care system is organized through referrals. Recommendations for improving interaction between the diabetes team (diabetologists, diabetes nurses, dietitians, chiropodists etc.) at the diabetes clinic, and general practice have been prepared by a working party for the Danish National Board of Health. General recommendations: (a) Appointment of a liaison committee in each county consisting of general practitioners (GPs), diabetologists, administrators, etc. (b) Employment of a GP at the diabetes clinic to take care of improving communication, teaching, research, quality assessment, etc. (c) Referral of all newly diagnosed patients with Type 1 diabetes and younger or complicated patients with Type 2 diabetes to the diabetes clinic. More far-reaching forms of co-operation to be discussed in the liaison committees include: (a) Based upon his own knowledge of where to look for help to solve a specific health problem, the diabetic patient may on his own initiative consult either the diabetes clinic or general practice. (b) Provision of access to consult the diabetes nurse/dietitian at the diabetes clinic for instruction without a formal referral. (c) Patients treated solely in general practice and thus unknown to the diabetes clinic may be referred or reported systematically to the diabetes clinic.

Entities:  

Mesh:

Year:  1994        PMID: 8181244     DOI: 10.1111/j.1464-5491.1994.tb00243.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  1 in total

1.  Danish general practitioners' estimation of urinary albumin concentration in the detection of proteinuria and microalbuminuria.

Authors:  N D Olivarius; C E Mogensen
Journal:  Br J Gen Pract       Date:  1995-02       Impact factor: 5.386

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.